Clinical Trial

3M™ Topical Tissue Adhesive Versus Commercially Available Tissue Adhesive for the Closure of Lacerations and Incisions

Study acronym: Lublin
Terminated
View on ClinicalTrials.gov →
Why the trial stopped
The business has decided to no longer support further development of this product. This decision was informed by a range of factors including the preliminary safety signals observed in the routine interim safety review and strategic reassessment
Summary
The purpose of this study is to generate safety and performance data for 3M™ Topical Tissue Adhesive. Enrolled subjects with qualifying trauma lacerations or surgical incisions will be randomized to receive 3M™ Topical Tissue Adhesive or Histoacryl® Blue Topical Skin Adhesive with follow-up visits at 10 days and 30 days after application of tissue adhesive.
Protocol Amendment History 6 changes
critical Trial status changed: Withheld → Terminated 2026-07-28
critical Trial terminated: The business has decided to no longer support further development of this product. This decision was informed by a rang... 2026-07-28
critical Primary endpoint(s) modified 2026-07-28
notable Enrollment changed: None -> 78 2026-07-28
notable Sponsor changed: [Redacted] -> Solventum US LLC 2026-07-28
minor Trial arms changed: 0 -> 2 2026-07-28
Trial Details
NCT Number NCT06217081
Lead Sponsor Solventum US LLC
Collaborators: United States Department of Defense, The University of Texas Health Science Center at San Antonio, 3M
Conditions Trauma-related Wound, Surgical Incision, Surgical Wound, Laceration
Enrollment 78 participants
Start Date 2024-10-28
Primary Completion 2025-06-24 (estimated)
Study Completion 2025-06-24 (estimated)
Updated on ClinicalTrials.gov 2026-07-27